Skip to main content

Table 1 Solicited adverse events after vaccinations at each dose in the study subjects (safety population)

From: Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial

 

Group (n)

No. (%) of subjects

p -value*

AE

no AE

Total

KD-287 (102)

87 (85.29)

15 (14.71)

0.050

JEV-GCC (102)

77 (75.49)

25 (24.51)

After 1st Vaccination

KD-287 (102)

65 (63.73)

37 (36.27)

0.118

JEV-GCC (102)

54 (52.94)

48 (47.06)

After 2nd Vaccination

KD-287 (102)

45 (44.12)

57 (55.88)

0.900

JEV-GCC (100)

45 (45.00)

55 (55.00)

After 3rd Vaccination

KD-287 (100)

46 (46.00)

54 (54.00)

0.394

JEV-GCC (96)

50 (52.08)

46 (47.92)

  1. AE, adverse event.
  2. *The p-value was calculated using the chi-square test.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us